The annual Conference on Retroviruses and Opportunistic Infections (CROI) was held on 4-7 March 2019, at the Washington State Convention Center in Seattle, Washington. CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.
At this year’s event, EPIICAL team member Sara Dominguez Rodriguez delivered the following oral presentation:
NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION
Alfredo Tagarro, Sara Dominguez Rodriguez, Thanyawee Puthanakit, Paolo Palma, Caroline Foster, Thidarat Jupimai, Nicola Cotugno, Jintanat Ananworanich, Santiago Jimenez de Ory, Paola Zangari, Maria Luisa Navarro, Paolo Rossi, Eleni Nastouli, Carlo Giaquinto, Pablo Rojo Conejo
This important study illustrated recent results that provide further evidence that supports the earliest antiretroviral therapy initiation in infants. Early antiretroviral therapy (ART) in children is associated with better clinical and virological outcome. The hypothesis explored is that HIV-perinatally infected neonates initiating ART within <7 days of life have a better long-term clinical and virological response than neonates treated ≥7 days and ≤28 days of life.
You can find the full webcast of the presentation here.